News

Early Results With Single-Agent Epcoritamab in Resistant CLL

Can Macrophage Activity Predict Immunotherapy Response in Patients With Melanoma?

Relapsed Mantle Cell Lymphoma: Treatment Strategies After CAR T-Cell Therapy

RMAT Designation Granted by the FDA for Gemogenovatucel-T in Advanced Ovarian Cancer

Long-Term Outcomes With Induction Therapies for Mantle Cell Lymphoma

Antithrombotic Therapy Concomitant With Immunotherapy in Advanced Melanoma

Neoadjuvant T-VEC: An Option for Cutaneous Basal Cell Carcinoma?

Subcutaneous Injection of Nivolumab and Hyaluronidase-nvhy Approved by the FDA

NSCLC: Another Cancer in Which CD47 Expression Makes a Difference

Updates From TRANSCEND CLL 004: Use of Lisocabtagene Maraleucel in CLL or SLL

AMPLIFY Trial Investigates Triplet Immunotherapy vs Chemoimmunotherapy in CLL

OASIS II: Triplet Immunotherapy Regimen for Treatment-Naive MCL

T-DXd Receives FDA Approval for Treatment of Select Patients With Metastatic Breast Cancer

Priority Review Granted by FDA for RP1 Plus Nivolumab in Advanced Melanoma

Combining Acalabrutinib and Rituximab in Older Patients With Mantle Cell Lymphoma

BRUIN CLL-321 Trial: Update on Pirtobrutinib for BTK Inhibitor–Pretreated CLL or SLL

Dato-DXd Approved by FDA for HR-Positive, HER2-Negative Breast Cancer

Research Focuses on How to Boost Immunotherapy Response in Recurrent Ovarian Cancer

Can Targeting SMARCA4 Overcome Ovarian Cancer Immune Evasion?

High-Grade Serous Ovarian Cancer: Molecular and Immune Diversity of mRNA Subtypes

C-POST Trial: Cemiplimab-rwlc After Surgery for High-Risk Squamous Cell Skin Cancer

Combination of Lisocabtagene Maraleucel and Ibrutinib in Aggressive CLL or SLL

Activity of Novel Antibody-Drug Conjugate in Resistant Mantle Cell Lymphoma

Acalabrutinib-Based Combination Under Study in Previously Untreated CLL

European Study on Chemoimmunotherapy vs BTK Inhibitors in CLL

Can Venetoclax Boost Response to CAR T-Cell Therapy in CLL?

Long-Term Outcomes of CAR T-Cell Therapy in Responders With CLL

Novel BTK Inhibitor–Based Combination First-Line Treatment of CLL

Triplet Regimen Under Study in Untreated CLL

Impact of Immunosenescence on CAR T-Cell Treatment in CLL

ZUMA-2 Trial Supports Brexucabtagene Autoleucel in BTK Inhibitor–Naive Relapsed or Refractory MCL

Adding BTK Inhibitor to Chemoimmunotherapy in Mantle Cell Lymphoma

Factors Influencing CAR T-Cell Therapy Outcomes in Recurrent Mantle Cell Lymphoma

Acalabrutinib Combination Therapy Approved by FDA for Previously Untreated MCL

Does Adding Palbociclib to Combination Therapy Improve Outcomes in Metastatic Breast Cancer?

Can Focused Ultrasound Improve Immunotherapy Response in Melanoma? Pilot Study Intends to Find Out

Are Sodium Levels a Prognostic Indicator of Survival in Metastatic NSCLC?